期刊文献+

急性前壁心肌梗死患者直接PCI后阿托伐他汀不同用药剂量疗效比较 被引量:2

Efficacy of Percutaneous Coronary Intervention for Acute Anterior Myocardial Infarction Patients with Two Kinds of Dosage for Atorvastatin
下载PDF
导出
摘要 为探讨直接经皮冠状动脉介入治疗(PCI)首次急性前壁心肌梗死患者,在不同剂量他汀药物治疗后住院期间疗效比较,纳入首次诊断为急性前壁心肌梗死并接受直接PCI治疗的患者140例,随机分为强化治疗组和对照组。强化治疗组入院时顿服阿托伐他汀80mg,术后40mg/晚,直至出院;对照组口服阿托伐他汀20mg/晚。术前及术后、出院前测定心肌标记物,术前及出院前测定血浆氨基末端B型利钠肽前体(NT-proBNP),采用彩色多普勒超声检测左室射血分数(LVEF)的变化,同时记录住院期间主要心脏不良事件(MACEs)的发生。结果出院时LVEF值差异无统计学意义(P=0.249),NT-proBNP出院前较术前升高,对照组升高显著(P=0.000)。组间比较NT-proBNP,对照组显著高于强化组(P=0.020)。住院期间两组患者无MACEs发生。首次急性前壁心肌梗死患者直接PCI后,强化阿托伐他汀治疗短期内可改善左心功能。 To study the efficacy of percutaneous coronary intervention for acute anterior myocardial infarction on patients with different doses statin therapy during hospitalization, a total of 140 patients with first acute anterior myocardial infarction were randomly divided into two groups. The experiment group was given 80 mg atorvastatin before PCI in combination with 40 mg atorvastatin after PCI, until discharge. The control group was given 20 mg atorvastatin each night. Before PCI, 24h after PCI and before discharge, the levels of cardiac markers were detected. NT-pro brain natriuretic peptide (NT-proBNP) and left ventricular ejection fraction (LVEF)that examined by using Doppler echocardiography were detected before the operation and discharge. The incidence of major adverse cardiovascular events was recorded during the period of hospitalization. Comparing between the two groups, the LVEF had no significant difference (P=0. 249). During the period of hospitalization, NT-proBNP in the control group was higher than before (P= 0.00). Compared with the study group, the level of NT-proBNP in the contrd group was significantly higher than that after the treatment (P=0.02). There were no major adverse cardiac events (MACEs) occurring during the hospitalization. Therefore, the intensive treatment of short-term atorvastatin can reduce the value of NT-proBNP, and can improve left ventricular function for patients with the first acute anterior myocardial infarction after directly to PCI.
出处 《医学与哲学(B)》 2014年第5期27-29,39,共4页 Medicine & Philosophy(B)
基金 科技部课题<以心血管系统疾病为主的临床药物评价研究技术平台的建设> 项目编号:2012ZX09303016-002 研究者发起的研究基金项目 项目编号:WS1803207
关键词 阿托伐他汀 急性心肌梗死 左心功能 氨基末端B型利钠肽前体 Atorvastatin, acute myocardial infarction, left ventricular function, NT-pro brain natriuretic peptide
  • 相关文献

参考文献18

  • 1Santoro G M,Carrabba N,Migliorini A,et al. Acute heart failure in pa- tients with acute myocardial infarction treated with primary percutane- ous coronary intervention[J]. Eur J Heart Fail,2008,10(8) :780-785.
  • 2刘海伟,韩雅玲.急性ST段抬高型心肌梗死再灌注治疗的急缓之择[J].医学与哲学(B),2012,33(1):44-45. 被引量:5
  • 3Bassan R, Potsch A, Maisel A, et al. B-type natriuretic peptide: a novel early blood marker of acute myocardial infarction in patients with chest pain and no ST-segment elevation[J]. Eur Heart J, 2005,26(3) :234 -240.
  • 4郑基能.心力衰竭患者血浆脑钠肽水平的变化及其临床意义探讨[J].吉林医学,2011,32(30):6316-6317. 被引量:5
  • 5刘永岭,张厚亮,刘建军,Mahande,王佩显.左心功能不全患者超声参数与血浆NT-proBNP的关系[J].放射免疫学杂志,2007,20(1):80-82. 被引量:3
  • 6Potocki M, Mair J, Weber M, et al. Relation of N-terminal pro-B- type natriuretic peptide to symptoms, severity, and left ventricular remodeling in patients with organic mitral regurgitation[J]. Am J Cardiol, 2009,104(4) : 559- 564.
  • 7Di Sciascio G, Patti G, Pasceri V, et al. Efficacy of atorvastatin re- load in patients on chronic statin undergoing percutaneous coronary intervention : results of the ARMYDA-RECAPTURE( Atorvastatin for Reduction of Myocardial Damage During Angioplasty)Random- ized Trial [J]. J Am Coil Cardiol,2009,54(6) :558-565.
  • 8Briguori C,Visconti G, Focaccio A, et al. Novel approaches for pre- venting or limiting events (NAPLES) Ⅱ trial:impact of a sigle high loading dose of atorvastatin on periprocedural myocardial infarction [J]. J Am Coil Cardio1,2009,54(23) :2157-2163.
  • 9Foody J M, Shah R, Galusha D, et al. Statins and mortality among elderly patients hospitalized with heart failure [J]. Circulation, 2006,113(8):1086-1092.
  • 10郭亮,高远,张海山,关启刚,田文,贾大林,孙英贤.强化他汀治疗对急性冠脉综合征行介入治疗患者的疗效与安全性[J].中国循证心血管医学杂志,2013,5(4):377-379. 被引量:16

二级参考文献57

  • 1杨艳敏,朱俊,谭慧琼,梁岩,章晏,李建东,刘力生,CREATE中国课题组.中国ST段抬高的急性心肌梗死临床特征及治疗现状[J].中华医学杂志,2005,85(31):2176-2182. 被引量:85
  • 2江洁华,廖伟娇,高启键,欧阳立杰,区碧茹.血清BNP测定在充血性心力衰竭诊断中的应用[J].热带医学杂志,2006,6(2):178-180. 被引量:7
  • 3颜雯,赵水平.从指南看冠心病降脂治疗的现状及分析[J].医学与哲学(B),2006,27(4):56-59. 被引量:7
  • 4HUNT S A, ABRAHAM W T, CHIN M H, et al. ACC/AHA 2005 guideline update for the diagnosis and management ofchronic heart failure in the adults[J]. Circulation, 2005, 112 (12) : 154-235.
  • 5Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the joint international and federation ofcardiology World Health Organization task force standardization of clinical nomenclature [ J ]. Circulation, 1979, 59(6): 607-609.
  • 6DAYER M, COWIE M R. Heart failure: diagnosis and healthcare burden[J]. Clin Med, 2004, 4( 1 ) : 13-18.
  • 7ATS stalement:guidelines for the six-minute walk test. ATS committee on proficiency standards for clinical pulmonary function laboratories [J]. Am J Respir Crit Care Med, 2002, 166(1): 111-117.
  • 8PLIQUETT R U, CORNISH K G, PEULER J D. Simvastatin normalizeneural control in experimental heart failure [ J ]. Circul- ation, 2003, 107(19): 2493-2498.
  • 9KANTOR P F, LUCIEN A, KOZA K R, et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondriallong-chain 3-ketoacyl coenzyme [J]. Athiolase Circ Res, 2000, 86(5): 580-588.
  • 10FEOLA M, BIGGI A, FRANCINI A, et al. Placebo of trimetazidine (99 m)Tc Tetrofosm in myocardial SPECT and low-dose dobutamine echoeardiography in liberating myocardium [ J ]. Arch Med Res, 2006, 37 ( 1 ) : 117-122.

共引文献74

同被引文献31

  • 1胡大一.心血管内科学[M].北京:人民卫生出版社,2009:248-250.
  • 2Kloner R A,Ganote C E,Jennings R B. Thc "no-reflow" phenome non after temporary coronary occlusion in the dog[J]. Clin Invest 1974,54 :1496-1508.
  • 3Niceoli G,Kharbanda R K, Crea F, et al. Nc~reflow: again prevention is better than treatment [J].Eur Heart J,2010,31(20) :2449- 2455.
  • 4Yip H K,Chen M C, (;hang H W, et al. Angiographie morphologic features of infarct-related arteries and timely reperfuslon in acute myocardial infarction: predictors of slow-flow and no-reflow phe nomenon[J]. Chest,2002,122(4) :1322-1332.
  • 5Zhao J L, Yang Y J,Cui C J, et at. Pretreatment with simvastatin reduces myocardial no reflow by opening mitochondrial K (ATP) channel[J]. Br J Pharmacol,2005,149(3) :243-249.
  • 6Yun K H,Shin I S,Shin S N,et al. Effect of previous statin therapy in patients with acute coronary syndrome and percutaneous coro naryintervention[J].Korean Circ J,2011,41(8):458- 463.
  • 7Yang Y J,Qian H Y,Huang J,et al. Combined therapy with simv astatin and bone marrow-derived mesenchymal stem cells increases benefits in infarcted swine hearts[J]. Arterioscler Thromb Vasc Bi oi,2009,29(12) :2076 -2082.
  • 8Iwakura K,ho H,Kawano S, et al. Chronic pre-treatment of statins is associated with the reduction of the no-reflow phenomenon in the patients with reperfused acute myocardial infarction[J]. Eur Heart J,2006,27(5) :534-539.
  • 9中华医学会心血管分会,中华心血管病杂志编委会.急性ST段抬高型心肌梗死诊断和治疗指南[J].中华心血管病杂志,2010;8(38):675-90.
  • 10MURRY C E,JENNINGS R B, REIMER K A, et al. Precondition ing with isehemia: A delay o{ lethal cell injury in ischemic myocardium[J]. Circulation, 1986,74(5):1124 1136.

引证文献2

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部